PT  - JOURNAL ARTICLE
AU  - Adams, Emily R
AU  - Augustin, Yolanda
AU  - Byrne, Rachel L
AU  - Clark, David J
AU  - Cocozza, Michael
AU  - Cubas-Atienzar, Ana I
AU  - Cuevas, Luis E.
AU  - Cusinato, Martina
AU  - Davies, Benedict M O
AU  - Davis, Mark
AU  - Davis, Paul
AU  - Duvoix, Annelyse
AU  - Eckersley, Nicholas M
AU  - Edwards, Thomas
AU  - Fletcher, Tom
AU  - Fraser, Alice J
AU  - Garrod, Gala
AU  - Hadcocks, Linda
AU  - Hu, Qinxue
AU  - Johnson, Michael
AU  - Kay, Grant A
AU  - Keymer, Katherine
AU  - Kirwan, Daniela
AU  - Klekotko, Kesja
AU  - Lewis, Zawditu
AU  - Mason, Jenifer
AU  - Mensah-Kane, Josie
AU  - Menzies, Stefanie
AU  - Monahan, Irene
AU  - Moore, Catherine M
AU  - Nebe-von-Caron, Gerhard
AU  - Owen, Sophie I
AU  - Planche, Tim
AU  - Sainter, Chris
AU  - Schouten, James
AU  - Staines, Henry M
AU  - Turtle, Lance
AU  - Williams, Chris
AU  - Wilkins, John
AU  - Woolston, Kevin
AU  - Sall, Amadou Alpha
AU  - Fitchett, Joseph R A
AU  - Krishna, Sanjeev
TI  - Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration
AID  - 10.1101/2020.04.29.20082099
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20082099
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20082099.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20082099.full
AB  - Here we describe an open and transparent consortium for the rapid development of COVID-19 rapid diagnostics tests. We report diagnostic accuracy data on the Mologic manufactured IgG COVID-19 ELISA on known positive serum samples and on a panel of known negative respiratory and viral serum samples pre-December 2019.In January, Mologic, embarked on a product development pathway for COVID-19 diagnostics focusing on ELISA and rapid diagnostic tests (RDTs), with anticipated funding from Wellcome Trust and DFID.834 clinical samples from known COVID-19 patients and hospital negative controls were tested on Mologic’s IgG ELISA. The reported sensitivity on 270 clinical samples from 124 prospectively enrolled patients was 94% (95% CI: 89.60% - 96.81%) on day 10 or more post laboratory diagnosis, and 96% (95% CI: 84.85% - 99.46%) between 14–21 days post symptom onset. A specificity panel comprising 564 samples collected pre-December 2019 were tested to include most common respiratory pathogens, other types of coronavirus, and flaviviruses. Specificity in this panel was 97% (95% CI: 95.65% - 98.50%).This is the first in a series of Mologic products for COVID-19, which will be deployed for COVID-19 diagnosis, contact tracing and sero-epidemiological studies to estimate disease burden and transmission with a focus on ensuring access, affordability, and availability to low-resource settings.Competing Interest StatementSK is a member of the Scientific Advisory Committee for Foundation for Innovative New Diagnostics (FIND) a not-for-profit that produces global guidance on affordable diagnostics. The views expressed here are personal opinions and do not represent the recommendations of FIND.Funding StatementThe group are supported by a DFID/Wellcome Epidemic Preparedness coronavirus grant, number 220764/Z/20/Z. ERA, LEC and LT are affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England. HMS is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George’s University of London. LT is supported by the Wellcome Trust (grant number 205228/Z/16/Z).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data available